Abiopharma

🔍 Szwarcberg Javier B. (Executive)

Company: SPRUCE BIOSCIENCES, INC. (SPRB)

Report Date: 2025-12-11

Detailed Transactions and Holdings:

• Acquired 10,000 shares of Employee Stock Option (right to buy) at $104.13 per share (Derivative)
  Date: 2025-12-11 | Code: A | Expires: 2032-01-02 | equity_swap_involved: 0 | shares_owned_after: 10,000.00 | transaction_form_type: 4 | Footnotes: F2, F1
• Sold 10,000 shares of Employee Stock Option (right to buy) at $344.25 per share (Derivative)
  Date: 2025-12-11 | Code: D | Expires: 2032-01-02 | equity_swap_involved: 0 | transaction_form_type: 4 | Footnotes: F2, F1

Footnotes:

• F1: The shares subject to the stock option vest over a four-year period commencing January 3, 2022, with 1/4th of the shares vested on January 3, 2023 and 1/36th of the remaining shares vesting on a monthly basis, subject to Reporting Person's Continuous Service (as defined in the Issuer's 2020 Equity Incentive Plan).
• F2: The transactions reported herein reflect a one-time stock option repricing (the "Option Repricing") effective on December 11, 2025 (the "Repricing Date"). The Option Repricing applies to options with exercise prices of $106.09 per share or greater held by employees and directors of the Issuer who remained in continuous service with the Company as of the Repricing Date.
• F3: Pursuant to the Option Repricing, the exercise price of the repriced options has been amended to reduce the exercise price to $104.13 per share, the thirty (30)-day trailing volume-weighted average price of the Common Stock on the Nasdaq Capital Market on the Repricing Date. However, if an optionholder exercises a repriced option before the end of a retention period of one year (which period may be shorter in certain circumstances), such optionholder will be required to pay the original exercise price per share of such repriced option. No other changes were made to the repriced options in connection with the Option Repricing, including with respect to the vesting schedules, expiration dates or number of shares underlying such repriced options.